Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers

NCT07254325 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

114

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

BIOLOGICAL: Secukinumab 150mg s.c.

Sponsor

Taizhou Mabtech Pharmaceutical Co.,Ltd